# RASolve 301 (NCT06881784)

> Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06881784
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions: daraxonrasib; docetaxel
- Enrollment: 590
- Primary outcome: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
- Primary outcome: Overall survival (OS) in the RAS G12X-C population

## Commentary we found

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rasolve-301-nct06881784